Expert Opinion on the Prescription Practice of Proton Pump Inhibitor for the Treatment of Gastroesophageal Reflux Disease
Published: 2024-02-21
Page: 37-43
Issue: 2024 - Volume 7 [Issue 1]
Manjula S. *
Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India.
Krishna Kumar M.
Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India.
*Author to whom correspondence should be addressed.
Abstract
Objective: To identify and evaluate the ideal therapeutic option for the management of gastroesophageal reflux disease (GERD) and associated nighttime heartburn in Indian settings with a special focus on rabeprazole prescription practice.
Methods: The cross-sectional, multiple-response questionnaire-based study was conducted among physicians specialized in the management of GERD. The questionnaire-based survey covered various aspects of GERD management, with a particular focus on the prescription preferences of rabeprazole.
Results: The survey collected responses from 192 experts, assessing their preference for proton pump inhibitors (PPIs) with 24-hour action. Approximately 91% of respondents favored rabeprazole over omeprazole and pantoprazole. Furthermore, approximately 53% of experts reported a higher incidence of GERD in subjects aged 40-55 years compared to other age groups. Obesity emerged as the predominant comorbid condition among patients experiencing nighttime heartburn associated with GERD. Rabeprazole was the preferred choice for managing nighttime heartburn with GERD symptoms, as indicated by 95% of experts. An overwhelming 97% and 90% of respondents preferred rabeprazole, acknowledging its rapid onset of action and suitability for long-term administration in the context of nighttime heartburn among GERD patients. Notably, 83% of the respondents preferred using domperidone as the prokinetic agent, particularly in conjunction with rabeprazole for the management of functional dyspepsia and gastroparesis.
Conclusion: Among other PPIs, rabeprazole was the preferred choice among experts for GERD management and nighttime heartburn relief, emphasizing its effectiveness in improving the quality of life for GERD patients. Also, it was also noted that domperidone was the preferred prokinetic agent for clinical use in combination with rabeprazole for the management of functional dyspepsia and gastroparesis.
Keywords: Gastroesophageal reflux disease, rabeprazole, domperidone, dyspepsia, heartburn
How to Cite
References
Lee SW, Lee TY, Lien HC, Peng YC, Yeh HJ, Chang CS. Correlation between symptom severity and health-related life quality of a population with gastroesophageal reflux disease. Gastroenterology Res. 2017;10(2):78–83.
Wang RH. From reflux esophagitis to Barrett's esophagus and esophageal adenocarcinoma. World J Gastroenterol. 2015;21(17):5210–9.
Bhatia SJ, Makharia GK, Abraham P, Bhat N, Kumar A, Reddy DN, et al. Indian consensus on gastroesophageal reflux disease in adults: A position statement of the Indian Society of Gastroenterology. Indian J Gastroenterol. 2019;38(5):411-440.
Shin JM, Sachs G. Long lasting inhibitors of the gastric H, K-ATPase. Expert Rev Clin Pharmacol. 2009;2(5):461–8.
Cammarota S, Bruzzese D, Sarnelli G, Citarella A, Menditto E, Riegler S, et al. Proton pump inhibitors prescribing following the introduction of generic drugs. European Journal of Clinical Investigation. 2012;42(10):1068–78.
Boardman HF, Delaney BC, Haag S. Partnership in optimizing management of reflux symptoms: a treatment algorithm for over-the-counter proton-pump inhibitors. Current Medical Research and Opinion. 2015;31(7):1309–18.
Haag S, Andrews JM, Katelaris PH, Gapasin J, Galmiche JP, Hunt R, et al. Management of reflux symptoms with over-the-counter proton pump inhibitors: issues and proposed guidelines. Digestion. 2009;80(4):226-34.
Dekkers, Beker, Thjodleifsson, Gabryelewicz, Humphries, European rabeprazole study group. Comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of active gastric ulcer—a European multicentre study. Aliment Pharmacol Ther. 1998;12(8):789-95.
Xia XM, Wang H. Gastroesophageal Reflux Disease Relief in Patients Treated with Rabeprazole 20 mg versus Omeprazole 20 mg: A Meta-Analysis. Gastroenterology Research and Practice. 2013;2013:e327571.
Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther. 2001;23(7):998-1017.
Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther. 1998;12(12):1235-40.
Galmiche JP, Zerbib F, Ducrottè P, Fournet J, Rampal P, Avasthy N, et al. Decreasing oesophageal acid exposure in patients with GERD: A comparison of rabeprazole and omeprazole. Aliment Pharmacol Ther. 2001;15(9):1343-50.
Pilotto A, Franceschi M, Leandro G, Scarcelli C, D'Ambrosio LP, Paris F, et al. Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. World J Gastroenterol. 2007;13(33):4467-72.
Carswell CI, Goa KL. Rabeprazole. Drugs. 2001;61(15):2327–56.
Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999; 340(11):825-31.
Alshammari SA, Alabdulkareem AM, Aloqeely KM, Alhumud MI, Alghufaily SA, Al-Dossare YI, et al. The Determinants of the Quality of Life of Gastroesophageal Reflux Disease Patients Attending King Saud University Medical City. Cureus. 2020;12(8):e9505.
Thalheimer A, Bueter M. Excess Body Weight and Gastroesophageal Reflux Disease. Visceral Medicine. 2021; 37(4):267–72.
Pehlivanov ND, Olyaee M, Sarosiek I, McCallum RW. Comparison of morning and evening administration of rabeprazole for gastro-oesophageal reflux and nocturnal gastric acid breakthrough in patients with reflux disease: a double-blind, cross-over study. Aliment Pharmacol Ther. 2003;18(9):883-90.
Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L; FAST Trial Investigators. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther. 2002;16(3):445-54.
Shahani S, Sawant P, Dabholkar P. Rabeprazole plus domperidone: the answer for gastro-oesophageal reflux disease. J Indian Med Assoc. 2008; 106(4):264-68.